News
Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Media
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsTraining Academy
Conferences
Conference CoverageConference Listing
Publications
More
CME/CE
Continuing Education
Resources
Case-Based Digest Rx Road MapEvents
Partners

Subscribe

  • News
  • Media
  • Conferences
  • Publications
  • CME/CE
  • Resources
  • Subscribe
  • Partners
  • Brain Cancer
  • Breast Cancer
    • Metastatic Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Liver Cancer
    • Gastric Cancers
  • Genitourinary Cancer
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Cervical Cancer
    • Ovarian Cancer
  • Head and Neck Cancers
  • Hematology
    • Leukemia
    • Graft-Vs-Host Disease
    • Myeloproliferative Neoplasms
    • Multiple Myeloma
    • Lymphoma
  • Lung Cancer
  • Pediatric Cancer
  • Sarcomas
  • Skin Cancer
    • Melanoma
Advertisement

Kerry Nichols, RN, BSN, OCN

Advertisement

Articles by Kerry Nichols, RN, BSN, OCN

Kerry Nichols on a Nurse Navigator-Led Smoking Cessation Program

ByKerry Nichols, RN, BSN, OCN
August 3rd 2017

Kerry Nichols, RN, BSN, OCN, explains their nurse navigator-led smoking cessation program.

Advertisement

Latest Updated Articles

  • Kerry Nichols on a Nurse Navigator-Led Smoking Cessation Program
    Kerry Nichols on a Nurse Navigator-Led Smoking Cessation Program

    Published: August 3rd 2017 | Updated:



Advertisement
Advertisement

Trending on Oncology Nursing News

1

Opinion: CAR T-Cell Therapy Shows Promise in Gastric and GEJ Cancers

2

Real, Placebo Acupuncture Improve Cognitive Outcomes in Breast Cancer Survivors

3

T-DXd/Pertuzumab Combo Earns FDA Approval in Advanced HER2+ Breast Cancer

4

Maintenance Tucatinib/HP Improves PFS Post 2-Year Mark in HER2+ mBC

5

FDA OKs Subcutaneous Amivantamab Across All NSCLC Indications

  • About Us
  • Editorial Board
  • Contact Us
  • CancerNetwork.com
  • CureToday.com
  • OncLive.com
  • TargetedOnc.com
  • Advertise
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us